Business Description
Inhibikase Therapeutics is a clinical-stage drug development company focused on treating serious heart and lung conditions, particularly pulmonary arterial hypertension, a life-threatening illness that progressively damages blood vessels in the lungs. Its lead drug candidate, IKT-001, is a reformulated oral version of an existing medicine designed to deliver the same therapeutic benefits with fewer digestive side effects. The drug is currently being tested in a large global Phase 3 trial measuring improvements in lung blood flow and patients' physical endurance. Founded in 2008 and based in Wilmington, Delaware, the company holds an exclusive license for IKT-001 through a partnership arrangement with Pivot Holding LLC.
